G-CON designs, builds, and installs prefabricated cleanrooms, for pharmabiotech companies. G-CON’s POD product is a “plug-and-play”, fully functional, clean- room with lower total cost of ownership, faster delivery times, and more consistent quality. G-CON acquired Plasteurop to further our footprint into the site installed clean components market providing interior finish features for the life science, semi conductor and battery market expanding our offering and market opportunities.
G-CON
Overview
G-CON at a glance
Key developments 2022
G-CON acquired and integrated Plasteurop in 2022, a modular wall panel, ceiling, door, and window manufacturer utilizing fully automated panel manufacturing lines. The company reduced energy consumption at US Site by 11% through smart heating technologies. G-CON Clean Solutions was able to increase proportion of Alu HC vs MW core from 40% to 60% reducing carbon footprint. They also now supply 50% of our steel with decarbonation certificates (XCArb).
Sector
Biotech
Location
United States
SDG aligment
Environmental
Carbon intensity: Tons CO₂e per EUR m revenue
Total tons CO₂ emitted
Change from '21-'22
2022
+0%
29 626
2021
12 912
Monetized climate impact
-EURm
The figure represents the monetized value the company has on the environment. See chapter 4 for methodology.
Social
Full time employees
Turnover34%
Unadjusted gender pay gap1.3%
Gender balance, % females
%
Board
%
Management
%
All employees
Monetized employment impact
EURm
The figure represents the monetized value the company has as a quality employer. See chapter 4 for methodology.
Governance
Via Summa Compliance
%
✔ Code of conduct
✔ Supplier code of conduct
✘ Economic Sanctions
✔ Competition Law/Antitrust
✔ Data Protection/IT Security
✔ Anti-curruption
✔ Whistleblower
How G-CON is advancing ESG
G-CON has implemented a code of conduct to pledge the companies commitment to integrity, respect and equity. It also ensures accountability throughout the organization to ensures that all employees feel safe and fairly treated.
Board Gender Diversity
Plan to improve gender diversity towards 40% has been initiated, target to achieve this during 2023.
What are the challenges G-CON addresses?
~0-0years
average time from project conception to drug availability on the market
~0bn
average cost of getting a drug onto the market
How does G-CON help solve these challenges?
Reality today
Conventional drug manufacturing facilities and implementation processes are highly customized, inefficient and time and resource intensive causing unreliable delivery schedules and budgets.
G-CON approach
G-CON’s pre-fabricated standardized cleanroom solutions reduce the engineering design, facility construction, and qualification timelines while providing the highest level of quality, cost and schedule certainty for facility projects.
Aspirational future
The rapid and reliable deployment of manufacturing capability through industry adoption of standardized pre-fabricated facility solutions significantly improves global patient access to safe, high quality, and cost effective medicines and therapies.
What impact does G-CON create?
Total cleanrooms space (sqm)
Change from '21-'22
2027 target: 20 k
2022
+0%
8k
2021
7k
2020
6k
Who is impacted?
Drug developers and manufacturers are impacted directly through more rapid and efficient deployment of cleanroom facilities for providing infrastructure and capabilities to support their critical operations. Patients are impacted through improvement in the industry’s ability to provide broader and more timely access to medicines.
What are the impact considerations?
Additionality
Drug developers and manufacturers are impacted directly through more rapid and efficient deployment of cleanroom facilities for providing infrastructure and capabilities to support their critical operations. Patients are impacted through improvement in the industry’s ability to provide broader and more timely access to medicines.
Risks
G-CON’s impact on drug development and manufacturing infrastructure is dependent on 2 key drivers: 1) increased adoption of standardized, pre-fabricated and modular cleanroom solutions and 2) Industry funding and investment in new facility infrastructure to support capacity requirements.